The eyedrop formulation of UNR844 (lipoic acid/choline ester chloride) was acquired as part of the group’s buyout of privately-held ophthalmology biotech Encore Vision for $375 million upfront in 2017, and was designed to work by restoring the elasticity of the eye’s lens that declines with age.
Presbyopia is characterised by a progressive inability to focus on objects nearby, making everyday activities – such as reading – challenging. It is estimated that more than 80% of adults over the age of 45 develop the condition.
